+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Plaque Psoriasis: 68-Market Analysis and Sales Forecast - Update (2025)

  • PDF Icon

    Report

  • 20 Pages
  • August 2025
  • Region: Global
  • GlobalData
  • ID: 6165049

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Plaque Psoriasis (PsO) market through 2030.

The analyst estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $30.1 billion, representing a compound annual growth rate (CAGR) of 10.0% over the 10-year forecast period. Major drivers of growth in the PsO market over the forecast period include a steady increase in total diagnosed prevalence across the 7MM and launches of five new pipeline agents: icotrokinra (JNJ-2113), sonelokimab, orismilast, piclidenoson, and TAK-279.

Across the 68 markets, sales in the PsO market were $16.4billion in 2020, growing to $44.0 billion in 2030. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 70.5% and 68.4% of 68-market sales in 2020 and 2030, respectively.

Scope

  • Overview of Plaque Psoriasis (PsO), including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized Plaque Psoriasis (PsO) therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PsO therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PsO treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global Plaque Psoriasis (PsO) therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM and 68M Plaque Psoriasis (PsO) therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM and 68M Plaque Psoriasis (PsO) therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Executive Summary
1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders and payers interviewed for this report
2.3.1 Key opinion leaders
2.3.2 Payers
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Analyst
2.5.2 Therapy Area Director
2.5.3 Epidemiologist
2.5.4 Epidemiology reviewers
2.5.5 Vice President of Disease Intelligence and Epidemiology
2.5.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
3 About the Analyst
  • Contact the Publisher
List of Tables
Table 1: PsO market size across the 68M - 7MM versus 61M
Table 2: PsO market size across the 68M - by geographical region
Table 3: PsO, key events occurring in the 7MM driving forecast trajectory in the 68M
Table 4: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: PsO market size across the 68M - 7MM versus 61M
Figure 2: PsO market size across the 68M - by geographical region

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen Inc
  • Organon
  • Leo Pharmaceuticals
  • Arcutis Biotherapeutics
  • AbbVie
  • BMS
  • Janssen
  • Johnson & Johnson
  • Novartis
  • UCB
  • AstraZeneca
  • Sun Pharma
  • Bausch Health
  • Union Therapeutics
  • Can-Fite Biopharma
  • Alumis
  • Lilly
  • Takeda
  • MoonLake Immunotherapeutics
  • Bristol-Myers Squibb Co
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Co Ltd
  • Sanofi
  • AbbVie Inc
  • UCB Inc
  • Johnson and Johnson, Inc.
  • Union Therapeutics AS
  • Janssen
  • LEO Pharma
  • Dermavant Sciences Inc
  • Arcutis Biotherapeutics Inc
  • MoonLake Immunotherapeutics
  • Bausch Health